Logo image of BTLS.BR

BIOTALYS NV (BTLS.BR) Stock Fundamental Analysis

EBR:BTLS - Euronext Brussels - BE0974386188 - Common Stock - Currency: EUR

3.17  -0.01 (-0.31%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to BTLS. BTLS was compared to 62 industry peers in the Chemicals industry. While BTLS seems to be doing ok healthwise, there are quite some concerns on its profitability. BTLS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BTLS had negative earnings in the past year.
BTLS had a negative operating cash flow in the past year.
BTLS had negative earnings in each of the past 5 years.
In the past 5 years BTLS always reported negative operating cash flow.
BTLS.BR Yearly Net Income VS EBIT VS OCF VS FCFBTLS.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -5M -10M -15M -20M

1.2 Ratios

BTLS's Return On Assets of -69.57% is on the low side compared to the rest of the industry. BTLS is outperformed by 90.32% of its industry peers.
Looking at the Return On Equity, with a value of -104.77%, BTLS is doing worse than 85.48% of the companies in the same industry.
Industry RankSector Rank
ROA -69.57%
ROE -104.77%
ROIC N/A
ROA(3y)-42.02%
ROA(5y)-36.72%
ROE(3y)-56.2%
ROE(5y)-49.38%
ROIC(3y)N/A
ROIC(5y)N/A
BTLS.BR Yearly ROA, ROE, ROICBTLS.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BTLS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BTLS.BR Yearly Profit, Operating, Gross MarginsBTLS.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

6

2. Health

2.1 Basic Checks

BTLS has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, BTLS has a worse debt to assets ratio.
BTLS.BR Yearly Shares OutstandingBTLS.BR Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M
BTLS.BR Yearly Total Debt VS Total AssetsBTLS.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

BTLS has an Altman-Z score of 5.38. This indicates that BTLS is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of BTLS (5.38) is better than 96.77% of its industry peers.
BTLS has a Debt/Equity ratio of 0.23. This is a healthy value indicating a solid balance between debt and equity.
BTLS has a Debt to Equity ratio of 0.23. This is in the better half of the industry: BTLS outperforms 72.58% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Altman-Z 5.38
ROIC/WACCN/A
WACCN/A
BTLS.BR Yearly LT Debt VS Equity VS FCFBTLS.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 3.88 indicates that BTLS has no problem at all paying its short term obligations.
BTLS's Current ratio of 3.88 is amongst the best of the industry. BTLS outperforms 91.94% of its industry peers.
A Quick Ratio of 3.88 indicates that BTLS has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.88, BTLS belongs to the top of the industry, outperforming 95.16% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.88
Quick Ratio 3.88
BTLS.BR Yearly Current Assets VS Current LiabilitesBTLS.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 11.74% over the past year.
EPS 1Y (TTM)11.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.2%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, BTLS will show a very negative growth in Earnings Per Share. The EPS will decrease by -43.83% on average per year.
BTLS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 56.92% yearly.
EPS Next Y0%
EPS Next 2Y-45.55%
EPS Next 3Y-28.96%
EPS Next 5Y-43.83%
Revenue Next Year233.33%
Revenue Next 2Y15.47%
Revenue Next 3Y18.56%
Revenue Next 5Y56.92%

3.3 Evolution

BTLS.BR Yearly Revenue VS EstimatesBTLS.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2023 2024 2025 2026 2027 2M 4M 6M 8M
BTLS.BR Yearly EPS VS EstimatesBTLS.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BTLS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BTLS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BTLS.BR Price Earnings VS Forward Price EarningsBTLS.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BTLS.BR Per share dataBTLS.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6 -0.8

4.3 Compensation for Growth

BTLS's earnings are expected to decrease with -28.96% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-45.55%
EPS Next 3Y-28.96%

More info and screens

0

5. Dividend

5.1 Amount

BTLS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOTALYS NV

EBR:BTLS (4/25/2025, 7:00:00 PM)

3.17

-0.01 (-0.31%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners23.43%
Inst Owner ChangeN/A
Ins Owners4.85%
Ins Owner ChangeN/A
Market Cap118.78M
Analysts87.5
Price Target6.58 (107.57%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)24.04%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.07
P/tB 6.26
EV/EBITDA N/A
EPS(TTM)-0.65
EYN/A
EPS(NY)-0.82
Fwd EYN/A
FCF(TTM)-0.44
FCFYN/A
OCF(TTM)-0.43
OCFYN/A
SpS0
BVpS0.52
TBVpS0.51
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -69.57%
ROE -104.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.02%
ROA(5y)-36.72%
ROE(3y)-56.2%
ROE(5y)-49.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 17.84%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.88
Quick Ratio 3.88
Altman-Z 5.38
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)53.61%
Cap/Depr(5y)129.78%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.2%
EPS Next Y0%
EPS Next 2Y-45.55%
EPS Next 3Y-28.96%
EPS Next 5Y-43.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year233.33%
Revenue Next 2Y15.47%
Revenue Next 3Y18.56%
Revenue Next 5Y56.92%
EBIT growth 1Y7.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year34.48%
EBIT Next 3Y4.4%
EBIT Next 5Y-24.57%
FCF growth 1Y15.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.09%
OCF growth 3YN/A
OCF growth 5YN/A